Community/Retail

Jeff Fudin, PharmD, FCCP, argues that the way to make hydrocodone combination products safer for patients is to provide more education for those who prescribe the medications and pharmacists who dispense them.

Mary Lynn McPherson, PharmD, explains why hydrocodone combination products should no longer be categorized as Schedule III drugs.

Post-myocardial infarction patients who had each of their preventive medications on hand at least 80% of the time had significantly lower rates of major vascular events or revascularization than controls.

A new study provides evidence that diabetes patients should receive the influenza vaccine, though its results are not as strong as those produced by previous studies.

Jeff Fudin, PharmD, FCCP, argues that categorizing hydrocodone combination products as Schedule II could lead to increased prescription of codeine, a much "sloppier" drug that could create problems for patients.

A study finds that children who develop hyponatremia after surgery for intracranial tumors are at heightened risk for a range of negative outcomes.

Mary Lynn McPherson, PharmD, argues that rescheduling hydrocodone combination products will lead to more responsible prescribing of the drugs and monitoring of their use.

Medication use improved in COPD and asthma patients whose community pharmacists intervened to address a range of potential problems.

Jeff Fudin, PharmD, FCCP, discusses the effect of rescheduling hydrocodone combination products as CII in New York State on prescription of other opioids, including oxycodone.

A report from IMS Institute for Healthcare Informatics finds that many pharmaceutical companies are lagging when it comes to engaging patients via social media.

Paying attention to how leaders in health-system pharmacy see the field changing can help one anticipate changes in other areas of pharmacy.

Patients who consistently used an online portal to refill their statin prescriptions had significantly increased medication adherence and improved LDL cholesterol control.

Mary Lynn McPherson, PharmD, explains how rescheduling hydrocodone combination products as Schedule II drugs will help reduce levels of abuse.

Jeff Fudin, PharmD, FCCP, argues that studies comparing the abuse liability of hydrocodone combination products with that of other opioids have produced conflicting results.

A new study estimates the costs of treating atrial fibrillation as well as the comparative costs of treating it with warfarin and newer oral anticoagulants.

Mary Lynn McPherson, PharmD, discusses why hydrocodone combination products were categorized as Schedule III in the first place.

A survey of pharmacy directors finds that they blame drug shortages for causing medication errors and adding to institutional costs.

If you really want to get your finances in order, you might want to consider going on an all-cash diet.

A study of COPD patients found that, on average, their exercise capacity declined over time and that just 5% enrolled in pulmonary rehabilitation, an intervention that has been shown to improve outcomes.

Jeff Fudin, PharmD, FCCP, argues that categorizing hydrocodone combination products as Schedule II drugs is unlikely to reduce abuse of the medications.

The agency has asked prescribers not to prescribe medications containing more than 325 mg of acetaminophen per dose.